Clinical Trials Logo

ECL-cell Hyperplasia clinical trials

View clinical trials related to ECL-cell Hyperplasia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02620696 Completed - Dyspepsia Clinical Trials

Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin

Start date: November 2009
Phase: Phase 1
Study type: Interventional

Hypergastrinaemia induced by proton pump inhibitor (PPI) treatment is reported to cause ECL-cell and parietal-cell hyperplasia, and rebound hyperacidity and dyspepsia after PPI withdrawal. The objective of the study was to determine the dosage regimen of netazepide, a gastrin/CCK2 receptor antagonist, required to inhibit the trophic effects of PPI-induced hypergastrinaemia. Six groups of 8 healthy subjects participated in a randomised, double-blind, placebo-controlled exploratory study of esomeprazole 40 mg daily for 28 days, and netazepide 1, 5 or 25 mg, or placebo daily during the last 14 days of esomeprazole dosing, or 14 days after esomeprazole withdrawal. Serum gastrin and plasma chromogranin A (CgA) were measured regularly from study start until at least 1 week after the last dose. Dyspepsia was monitored after esomeprazole withdrawal.